ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

27 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

15 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 Dec 2024 12:00:28 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

24 Dec 2024 09:45:04 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 Dec 2024 09:57:16 By NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

09 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

02 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

26 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

17 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

06 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire